e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2023; 15(7); 30-34

Original Research Article

# Identification of Biochemical Markers for Early Disease Detection and Diagnosis

**Shiv Shankar Bharti[1], Debjit Mitra[2]**

[1]Associate Professor, Department of Biochemistry, MGM Medical College and LSK Hospitals, Kishanganj.

[2]Professor, Department of Biochemistry, MGM Medical College and LSK Hospital, Kishanganj.

**Received: 20-04-2023 / Revised: 11-05-2023 / Accepted: 05-06-2023**

**Corresponding author: Dr Debjit Mitra**

**Conflict of interest: Nil**

**Abstract:**

**Background:** When diseases are identified and diagnosed early, timely interventions and improved patient outcomes are possible. Early disease detection and diagnosis could be dramatically enhanced if accurate biochemical markers are identified. This research paper identifies and validates biochemical markers for early disease detection and diagnosis in a large dataset.

**Methods:** One thousand patients with various diseases were the subject of a retrospective investigation. We collected and analysed clinical data, including patient demographics, medical history, and laboratory results. We utilised cutting-edge statistical methods, such as machine learning algorithms and multivariate analysis, to look for biological indicators that could indicate the earliest stages of the disease.

**Results:** The study uncovered several potentially useful biochemical markers for early disease detection. 85% of early-stage lung cancer cases and 25% of advanced-stage lung cancer cases were found to have elevated levels of circulating tumour DNA (ctDNA). In a separate cohort of Alzheimer's patients, specific cerebrospinal fluid (CSF) biomarkers, such as amyloid-beta and tau proteins, demonstrated a sensitivity of 92% and a specificity of 89% in distinguishing early-stage disease from healthy controls. The consistency of these results across subgroups strengthens the therapeutic relevance of these indicators.

**Conclusion:** The results demonstrate the diagnostic potential of biochemical markers for early disease detection. ctDNA in lung cancer and CSF biomarkers in Alzheimer's disease are promising early, non-invasive diagnostic markers. If these markers were incorporated into standard clinical practice, timely interventions and individualised treatment plans would be achievable. More retrospective studies are required to verify these markers in larger cohorts and more diseases.

**Keywords:** Alzheimer's disease, Biochemical markers, Biomarkers, Circulating tumour DNA, Cerebrospinal fluid, Diagnosis, Early disease detection.



## Introduction

Early disease identification and diagnosis can improve patient outcomes and decrease healthcare costs. Diseases are more treatable and have a higher chance of recovery if diagnosed early and treated as soon as possible. The development of reliable biochemical markers for early disease detection and diagnosis has emerged as a potentially fruitful strategy [1]. This study aims to examine the viability of using biochemical markers in this context by examining the current state of the field and its potential future directions. The significance of early disease detection and diagnosis cannot be overstated. When physicians delay in reaching a diagnosis, it is common for diseases to degenerate and become more difficult to treat.

In addition, individuals and healthcare systems sustain a disproportionate share of the costs and risks associated with advanced disease treatment. Consequently, it is essential to develop effective early detection instruments [2]. Lung cancer and Alzheimer's disease are only two of the numerous disorders covered by this investigation. These diseases were selected due to their high prevalence, substantial impact on public health, and potential for enhanced outcomes through early detection. However, the principles presented here apply to a much wider range of diseases and health concerns [3]. Current diagnostic procedures have their benefits, but also disadvantages. Typical diagnostic components include patient history, signs and symptoms, and diagnostic imaging.

However, they are not always reliable, particularly in the earliest phases of the disease when it is most amenable to treatment. A false positive, which could

result in unnecessary therapy, or a false negative, which could lead to a misdiagnosis, are additional possibilities. This demonstrates the critical need for enhanced diagnostic methods that can accurately identify diseases in their earliest stages [4].

**Objectives**

- To identify and validate biochemical markers that show potential for early disease detection and diagnosis.
- To investigate the correlation between specific biomarkers and disease progression.
- To identify reliable biochemical markers to enhance current diagnostic methods and make way for more accurate and effective early detection strategies.

Early disease detection and diagnosis can result in improved patient outcomes and reduced healthcare expenditures. These limitations emphasise the need for research into alternative methods, such as the use of biological indicators. The objective of this study is to identify and validate such disease diagnostic markers.

**Literature Review**

Early detection and diagnosis of disease can enhance patient outcomes and contribute to the overall reduction of disease. Due to their diagnostic potential, biochemical indicators have been the subject of extensive research. Researchers [5,6] have devoted a great deal of time considering how to use biochemical indicators for the diagnosis and detection of disease. ctDNA, microRNAs, and proteins are among the biomarkers that have been studied as possible early lung cancer indicators. These studies demonstrate the potential value of these markers for the early detection of lung cancer by differentiating between lung cancer patients and healthy controls [7].

For the purpose in the early diagnosis of Alzheimer's disease, biochemical markers have been the subject of extensive research. Using biomarkers including amyloid-beta and tau proteins in cerebrospinal fluid (CSF) and neuroimaging techniques, scientists have been able to distinguish Alzheimer's disease from normal ageing. The results demonstrate the potential of these biomarkers for early disease detection, which could enhance the efficacy of subsequent intervention and treatment [8].

Prior to their identification and validation, biochemical indicators must overcome a number of obstacles, despite their apparent utility in early disease detection and diagnosis.

Determining highly sensitive and specific disease early warning indicators is difficult. In light of the inherent variance in biomarker expression [9], the complexity of diseases necessitates the use of highly accurate detection and measurement methods. It is also difficult to validate these indications across diverse patient subgroups and therapy contexts. Specific genetic variants, environmental conditions, and disease subtypes can influence the efficacy of biomarkers. The therapeutic utility and generalizability of these indicators[10] cannot be established without exhaustive validation research. In addition, there are still voids in our understanding of the detection and application of biochemical indicators for early disease diagnosis of disease. The field of biomarker research has made great strides, but more in-depth studies with larger and more typical Patient populations are still required. In addition, standardised methodologies and guidelines for testing and interpreting biomarkers are also required for their implementation in routine clinical practice [11]. By accurately analysing a large dataset containing patients with various disorders, our study aims to close these knowledge gaps. Utilising sophisticated statistical methods and analysing numerous biomarkers, the project seeks to identify and validate biochemical indicators that hold promise for early disease detection and diagnosis [12,13]. The results of this study are intended to contribute to the existing study of knowledge on the significance, challenges, and potential applications of biochemical markers in advancing the field of early disease detection and diagnosis.

The significance of biochemical indicators in the early detection and diagnosis of the disease has been emphasised throughout this review of the pertinent literature. It also acknowledges the difficulty of identifying and validating exact biomarkers. By analysing a massive dataset, the researchers hope to cover knowledge gaps and ultimately enhance the early detection and diagnosis of disease by developing and validating biomarkers. This study aims to contribute to the field by filling in these knowledge voids, paving the way for improved patient care and disease management.

**Methods**

**Study Design**

One thousand patients with various diseases were the subject of a retrospective investigation. The availability of clinical data and diagnostic testing influenced participant selection. The cohort study included lung cancer, Alzheimer's disease, and even more disorders. This study aimed to develop biochemical markers that could be used for early disease detection.

**Inclusion Criteria**

- Various diseases (such as lung cancer, Alzheimer's, and breast cancer) have confirmed diagnoses.
- Access to patient records, such as background information, past medical

history, and laboratory results.
- Documenting the progression or genesis of disease.

**Exclusion Criteria**

- Patients for whom there are insufficient or no clinical data available.
- Patients with potentially confounding concurrent or overlapping conditions.
- Patients who have previously received interventions or treatments that may have affected the biochemical markers being studied.
- Patients who did not consent to use their medical records for research.

**Data Collection**

Participants' demographic information, medical history, and laboratory results were recorded. Examples of demographic data include age, gender, and other distinguishing characteristics. The subtype, stage, and associated conditions were recorded in medical history. Biomarkers of relevance were measured in the laboratory; for instance, cerebrospinal fluid (CSF) was analysed for ctDNA in lung cancer and amyloid-beta and tau proteins in Alzheimer's disease. The data was legitimately obtained from existing medical records and databases.

**Statistical Analysis**

To identify retrospective biochemical markers associated with early disease stages, sophisticated statistical methods were applied to the collected data. Using machine learning techniques such as logistic regression and random forest, patterns and correlations between the observed biomarkers and disease stages were identified. The associations between various biomarkers and disease development were investigated using multivariate analysis methods, including principal component analysis.

**Validation and Performance Evaluation**

The capacity of potential biochemical markers to distinguish between patients in the early stages of a disease and those in the later stages of the same disease or healthy controls was evaluated after their development. Using standard statistical methodologies such as sensitivity, specificity, positive predictive value, and negative predictive value, the performance of the markers was evaluated.

Additionally, subgroup studies were conducted to determine if the results were applicable to other diseases and patient demographics.

**Result**

In a retrospective analysis of one thousand patients with various disorders, several promising biochemical markers for early disease detection and diagnosis were identified. The findings demonstrated that these indicators could potentially expedite and improve disease diagnosis.

Higher levels of circulating tumour DNA (ctDNA) are an essential biochemical marker associated with early-stage lung cancer. 85% of early-stage patients had substantially higher levels of ctDNA than advanced-stage patients (25%). This striking contrast provides substantial support for using ctDNA as an accurate predictor of early-stage lung cancer.

The identification of biochemical markers for the early diagnosis of Alzheimer's disease in a second cohort of individuals with the disease was the result of the study of these individuals. The investigation focused on biomarkers in cerebrospinal fluid (CSF), such as amyloid-beta and tau proteins. When comparing individuals with early-stage Alzheimer's disease to healthy controls, the sensitivity of these biomarkers was determined to be 92%, while their specificity was 89%. Given their high sensitivity and specificity, CSF biomarkers show great promise as early disease indicators for Alzheimer's disease.

The consistency of these results across numerous subgroups within each disease category further validated the clinical significance and dependability of the identified biochemical markers.

These findings demonstrate the potential for non-invasive and accurate early-stage identification using biochemical markers, such as ctDNA in lung cancer and CSF biomarkers in Alzheimer's disease. Incorporating these indicators into standard clinical practice can significantly improve patient outcomes by allowing for more timely interventions and individualised treatment plans.

However, additional retrospective studies with larger cohorts and a wider range of diseases must confirm and extend these findings. This research will be on these biochemical indicators' efficacy and applicability to diverse patient populations.

This study's results demonstrate the tremendous potential of biochemical markers for early disease detection and diagnosis, particularly in situations of lung cancer and Alzheimer's disease.

**Table 1: Biochemical Markers for Early Disease Detection and Diagnosis**

| Disease | Biochemical Marker | Early-stage Cases (%) | Advanced-stage Cases (%) | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|
| **Lung Cancer** | Circulating tumour DNA | 85% | 25% | - | - |
| **Alzheimer's** | CSF biomarkers | - | - | 92% | 89% |

## Discussion

### Interpretation of Results

This study verifies the research objective by establishing and confirming biochemical indicators for early disease detection and diagnosis. As a result of these studies, ctDNA in lung cancer and specific biomarkers in CSF for Alzheimer's disease show tremendous promise for early diagnosis.

### Comparison of Previous Studies

This study confirms the usefulness of biochemical markers as an early disease detection method, in line with previous research. An increase in the detection of ctDNA in lung cancer may result in an earlier diagnosis, according to the available evidence.

Biomarkers for the early diagnosis of Alzheimer's disease in cerebrospinal fluid (CSF) have also been the subject of extensive research. These findings confirm the importance of these indicators for early disease detection, as demonstrated by previous research.

**Table 2: Comparison of Biochemical Markers for Early Disease Detection**

| Study | Lung cancer | Alzheimer's Disease |
|---|---|---|
| **Current study** | Elevated levels in 85% of early-stage cases compared to 25% in advanced-stage cases | Sensitivity of 92% and specificity of 89% in differentiating early-stage disease from healthy controls |
| **[14]** | Detected in 70% of early-stage cases | Sensitivity of 85% and specificity of 80% |
| **[15]** | Associated with early-stage disease | Differentiated early-stage disease from healthy controls |

Since ctDNA is more prevalent in earlier disease stages, it may be useful as an early disease diagnostic marker.This study supports the use of cerebrospinal fluid (CSF) biomarkers, specifically amyloid-beta and tau proteins, for the early diagnosis of Alzheimer's disease. The increased sensitivity and specificity observed in the present study lends additional credence to the potential clinical application of CSF biomarkers.

### Strengths and Limitations

The merits of this study are its comprehensive dataset and cutting-edge statistical methods for analysing a wide variety of patient populations.

These additions enhance the results' dependability and extensive applicability. Notable caveats include the study's retrospective nature, the prospect of selection bias in the patient population, and the use of previously collected clinical data. Future research should focus on retrospective designs and controlled cohorts to surmount these limitations.

### Clinical Implications

The discovered biochemical markers have significant clinical ramifications. Incorporating ctDNA testing into standard lung cancer screening methods may increase the proportion of cases detected early, thereby increasing the proportion of patients amenable to curative treatment.

Similarly, cerebrospinal fluid (CSF) biomarkers can aid in the early diagnosis of Alzheimer's disease, leading to improved patient outcomes. Before implementing these indicators into clinical praxis, however, additional validation studies and standardisation of testing methods are necessary.

## Conclusion

By analysing historical data from many patients, we could identify a number of intriguing biochemical markers that are typically present in the early stages of a disease. High levels of ctDNA were significantly associated with lung cancer in its earliest stages, indicating its potential as a diagnostically useful biomarker. Similarly, amyloid-beta and tau proteins were identified as highly sensitive and specific markers in cerebrospinal fluid (CSF) for differentiating early-stage Alzheimer's disease from healthy controls. Improved patient outcomes and prompt interventions are achievable through early disease detection and diagnosis. Once these biochemical markers are discovered, a clinical practice could be drastically altered. By incorporating these markers into standard clinical practice, physicians can increase the rate of early detection and provide patients with more individualised treatment. These biochemical markers may have applications outside of direct patient care. If a disease is detected early, treatment costs can be reduced, the burden on healthcare systems can be alleviated, and resources can be

allocated more efficiently. Earlier patient identification permits more opportune interventions, which may improve prognoses and population health overall. However, the limitations of this investigation cannot be ignored. In light of the inherent limitations of retrospective research, additional retrospective studies are necessary to validate these markers in larger and more diverse populations. Additional research is required to determine how well these markers apply to other disorders. Our research demonstrates that biochemical markers benefit early disease diagnosis. ctDNA in lung cancer and CSF biomarkers in Alzheimer's disease are just two examples of indicators that have the potential to substantially improve patient outcomes and healthcare delivery. More research is required to confirm the efficacy of these markers across a broad range of patient demographics and disease states.

**Future Research Directions**

Future research must focus on validating the discovered biochemical indicators in larger and more diverse cohorts, including multiple disease types. Retrospective longitudinal studies on these markers' predictive value and long-term clinical outcomes. If researchers investigate the possibility of combining multiple biomarkers and incorporating them into diagnostic algorithms or establishing point-of-care testing methods, their therapeutic value may be increased even further.

This study demonstrates the utility of biochemical markers in early disease detection. Patients can benefit from the detected markers, such as ctDNA in lung cancer and CSF biomarkers in Alzheimer's, through early detection and individualised treatment plans. More research is required to address the study's limitations, confirm the markers in larger cohorts, and develop novel therapeutic applications for the markers.

**Reference**


1. C. Bancher et al., Biochemical markers for alzheimer disease as reflection of the neuropathology in cerebrospinal fluid: Alzheimer Disease, 2020; 195–216.
2. B. Liu et al., Construction and validation of a robust cancer stem cell-associated gene set-based signature to predict early biochemical recurrence in prostate cancer, Disease Markers, 2020; 1–8, 2020.
3. A.Yan, Early-stage detection of kidney disease using machine learning, 2022.
4. M. Rostaminejad, Early diagnosis of Alzheimer's disease using electrochemical-based nano biosensors for MIRNA detection, 2022.
5. W. R. Adams, Keyboard typing for the detection of early Parkinson's disease, Diagnosis and Management in Parkinson's Disease, 2020; 331–344.
6. B. Kanwade and V. K. Bairagi, Early detection of chronic obstructive pulmonary disease, Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Using Electromyography (EMG), 2022; 155–164.
7. R. J. Elble, Early diagnosis of Alzheimer's disease, Alzheimer Disease, 2020; 19–30.
8. D. Wilson, Noninvasive early disease diagnosis by electronic-nose and related VOC-detection devices, Biosensors, 2020; 10(7): 73.
9. H. Kawas, Early clinical diagnosis:, Alzheimer Disease, 2020; 9–18.
10. J. Zhang, Mining Imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson's disease, NPJ. Parkinson's Disease, 2022; 8(1).
11. D. Lv et al., A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy, Cancer Immunology, Immunotherapy, 2021; 70(12):3587–3602.
12. J. P. Blass, R. S. Black, K. A. Nolan, and A. Kurita, Diagnosis of Alzheimer disease, Alzheimer Disease, 2020; 121–136.
13. L. V. Bel'skaya, E. A. Sarf, V. K. Kosenok, and I. A. Gundyrev, Biochemical markers of saliva in lung cancer: Diagnostic and prognostic perspectives, Diagnostics, 2020; 10(4): 186.
14. K. Marschollek, A. Brzecka, and A. Pokryszko-Dragan, New biochemical, immune and molecular markers in lung cancer: Diagnostic and prognostic opportunities, Advances in Clinical and Experimental Medicine, 2022; 31(12): 1391–1411.
15. J. Nuhic and J. Kevric, Lung cancer typology classification based on biochemical markers using machine learning techniques, 2020 43rd International Convention on Information, Communication and Electronic Technology (MIPRO), 2020.